15.09.2014 • News • Bayer • Boston Scientific • Diabetes Care

Bayer Completes Sale of Interventional Device Business

Bayer HealthCare has completed the sale of its interventional device business to Boston Scientific for $ 415 million.

The German company said the divestment will allow its medical care division to concentrate on innovation and growth in radiology and diabetes care, where it already has a strong presence.

The transaction includes the AngioJet (thrombectomy) and Jetstream (atherectomy) systems, and the FetchAspiration catheter used in cardiology, radiology and peripheral vascular procedures.

Bayer's Interventional business had sales of $120 million in 2013.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Top-Feature